Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene

• Valerie Cornish, Katalin Pintér, +6 authors Edith Sim
• The Pharmacogenomics Journal
• 2003

ABSTRACTArylamine N-acetyltransferases (NATs) are polymorphic xenobiotic metabolising enzymes, linked to cancer susceptibility in a variety of tissues. In humans and in mice there are multiple NAT… (More)

Compiling High Performance Fortran for Distributed-memory Systems

• Jonathan Harris, John Bircsak, +6 authors Carl D. Offner
• Digital Technical Journal
• 1995

ming language for writing parallel programs. It is based on the Fortran 90 language, with extensions that enable the programmer to specify how array operations can be divided among multiple… (More)

A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer

• Neil W. Johnson, Valerie Speirs, Nicola J Curtin, Andrew G Hall
• Breast Cancer Research and Treatment
• 2007

Allelic imbalance is a common feature of many malignancies. We have measured allelic imbalance in genomic DNA from the breast cancer cell lines T47D, MDA-MB-231, two antiestrogen sensitive (MCF7N and… (More)

Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos.

• V. A. Smelt, Anna L. Upton, +5 authors Edith Sim
• Human molecular genetics
• 2000

Arylamine N -acetyltransferases (NATs) catalyse the acetylation from acetyl-CoA of arylamines and hydrazines. There are two human isoenzymes which show polymorphism, and both enzymes are involved in… (More)

N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast.

• Julie A. Williams, Elaine M. Stone, +6 authors David H Phillips
• Pharmacogenetics
• 2001

Heterocyclic amines are mammary carcinogens in rats and their N-hydroxy metabolites are substrates for subsequent metabolic activation by N-acetyltransferases (NAT) and sulfotransferases (SULT) in… (More)

Placental arylamine N-acetyltransferase type 1: potential contributory source of urinary folate catabolite p-acetamidobenzoylglutamate during pregnancy.

• Anna M. Upton, V. A. Smelt, +4 authors Edith Sim
• Biochimica et biophysica acta
• 2000

Human arylamine N-acetyltransferase type 1 (NAT1), better known as a drug-metabolising enzyme, has been proposed to acetylate the folate catabolite p-aminobenzoylglutamate (p-abaglu) to… (More)

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.

• Yifan Wang, Andrea J. Bernhardy, +35 authors Neil W. Johnson
• Cancer research
• 2016

Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits… (More)

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.

• Shawn F. Johnson, Cristina Cruz, +25 authors Geoffrey I. Shapiro
• Cell reports
• 2016

Although poly(ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance after restoration of HR. Here, we… (More)

RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.

• Yifan Wang, John J. Krais, +8 authors Neil W. Johnson
• The Journal of clinical investigation
• 2016

Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises… (More)

A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.

• Erin M George, Hyoung Kook Kim, +20 authors Fiona A Simpkins
• JCI insight
• 2017

Approximately 50% of high-grade serous ovarian cancers (HGSOCs) have defects in genes involved in homologous recombination (HR) (i.e., BRCA1/2). Preclinical models to optimize therapeutic strategies… (More)

• ‹
• 1
• 2
• ›